Haemonetics Corp Files 8-K

TL;DR

HAE filed an 8-K, likely containing important corporate updates.

AI Summary

Haemonetics Corporation filed an 8-K on December 3, 2024, to report other events and financial statements. The filing does not contain specific details about the nature of these events or financial figures within the provided text.

Why It Matters

This filing indicates that Haemonetics Corporation has made a regulatory submission to the SEC, which may contain important updates for investors.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for reporting events and financial statements, with no immediate indication of significant negative developments.

Key Players & Entities

• Haemonetics Corporation (company) — Registrant
• 0000313143-24-000066 (other) — Accession Number
• December 3, 2024 (date) — Report Date
• Massachusetts (location) — State of Incorporation
• 125 Summer Street Boston, MA 02110 (address) — Principal Executive Offices

FAQ

Key Financial Figures

• $44.6 million — turing facility in Tijuana, Mexico, for $44.6 million in cash and up to $22.5 million in cont
• $22.5 million — co, for $44.6 million in cash and up to $22.5 million in contingent consideration based on sa

Filing Documents

• hae-20241203.htm (8-K) — 29KB
• aex991xpressrelease1232024.htm (EX-99.1) — 13KB
• newlogoa.jpg (GRAPHIC) — 398KB
• 0000313143-24-000066.txt ( ) — 715KB
• hae-20241203.xsd (EX-101.SCH) — 2KB
• hae-20241203_lab.xml (EX-101.LAB) — 21KB
• hae-20241203_pre.xml (EX-101.PRE) — 12KB
• hae-20241203_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On December 3, 2024, Haemonetics Corporation (the "Company") announced that it has entered into a definitive agreement to sell its whole blood assets within its Blood Center business unit to GVS, S.p.A ("GVS"), a leading manufacturer of filter solutions for applications in the healthcare and life sciences sectors. Under the terms of the agreement, GVS will acquire the Company's complete portfolio of proprietary whole blood collection, processing and filtration solutions, along with the Company's manufacturing facility in Covina, California where certain of these products are produced, and related equipment and assets located at the Company's manufacturing facility in Tijuana, Mexico, for $44.6 million in cash and up to $22.5 million in contingent consideration based on sales growth over the next three years and achievement of certain other milestones. Haemonetics' Blood Center business will continue to manufacture and provide customers with its full line of apheresis solutions for automated blood collection, which include devices and disposable kits that support a variety of apheresis collections, including platelets, plasma and red cells, and ensure efficient blood center operations. The transaction is expected to close in the first quarter of calendar 2025, subject to the satisfaction of customary closing conditions. A copy of the Company's press release announcing the transaction is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The press release shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of such section, nor shall such information be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of the general incorporation language of such filing, except as shall be expressly set forth by specific reference in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release issued by Haemonetics Corporation on December 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HAEMONETICS CORPORATION December 3, 2024 By: /s/ Christopher A. Simon Name: Christopher A. Simon Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR